17 completed. 17 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Glomerulosclerosis, Focal Segmental: new trials by email Literature Review of Glomerulosclerosis, Focal Segmental trials Research Report on Glomerulosclerosis, Focal Segmental
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease Baricitinib, Placebo - Chronic Kidney Diseases | Phase 2 | Completed | Duke University | 8 | 2023-04-20 | 2026-04-24 |
| Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis R3R01 - Alport Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | River 3 Renal Corp. | 43 | 2022-06-15 | 2025-09-29 |
| Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis VX-147 - Glomerulosclerosis, Focal Segmental | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 16 | 2020-06-08 | 2025-09-24 |
| Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease adalimumab - FSGS, MCD | Phase 2 | Completed | University of Michigan | 7 | 2019-10-02 | 2024-10-30 |
| Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Propagermanium, Placebo - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Dimerix Bioscience Pty Ltd | 8 | 2018-11-08 | 2022-07-29 |
| A Study of CCX140-B in Subjects With FSGS Placebo, CCX140-B - FSGS, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Amgen | 46 | 2018-05-17 | 2025-03-13 |
| A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Bardoxolone methyl capsules - IgA Nephropathy, CKD Associated With Type 1 Diabetes | Phase 2 | Completed | Biogen | 103 | 2017-12-26 | 2025-06-03 |
| Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Abatacept, Normal Saline, D5W - Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Bristol-Myers Squibb | 36 | 2016-03-09 | 2021-03-05 |
| A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) Losmapimod - Glomerulosclerosis, Focal Segmental | Phase 2 | Completed | GlaxoSmithKline | 17 | 2014-07-01 | 2017-06-12 |
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis RE-021 (Sparsentan), Irbesartan - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Travere Therapeutics, Inc. | 109 | 2014-03-01 | 2025-05-15 |
| Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood Rituximab, Placebo - Childhood Idiopathic Nephrotic Syndrome | Phase 2 / Phase 3 | Completed | University Hospital, Limoges | 26 | 2010-12-01 | 2015-03-23 |
| Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial Adalimumab, Lisinopril, losartan, and atorvastatin, galactose - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | NYU Langone Health | 32 | 2008-12-01 | 2016-07-11 |
| Podocyte Retinoids Isotretinoin - Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 12 | 2004-11-26 | 2017-12-13 |
| Sirolimus for Focal Segmental Glomerulosclerosis Sirolimus - Focal Glomerulosclerosis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 30 | 2002-06-01 | 2008-03-04 |
| Permeability Factor in Focal Segmental Glomerulosclerosis Plasma exchange, Cyclophosphamide - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 15 | 2000-12-01 | 2016-02-10 |
| Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis Dexamethasone - Glomerulonephritis, Nephrotic Syndrome | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 20 | 2000-03-01 | 2008-03-04 |
| Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) Pirfenidone - Fibrosis, Focal Glomerulosclerosis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 21 | 1999-12-01 | 2014-05-26 |
Nephrotic Syndrome (8) · Proteinuria (5) · Fibrosis (3) · Nephrosis, Lipoid (3) · Kidney Diseases (2) · Renal Insufficiency (2) · Renal Insufficiency, Chronic (2) · Camurati-Engelmann Syndrome (1) · Glomerulonephritis (1) · Glomerulonephritis, IGA (1) · Macular dystrophy, corneal type 1 (1) · Nephritis, Hereditary (1) · Osteoporosis (1) · Polycystic Kidney, Autosomal Dominant (1)
Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Nephritis (17) · Urogenital Diseases (17) · Urologic Diseases (17) · Glomerulonephritis (16) · Kidney Diseases (15) · Nephrosis (8) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (5) · Urination Disorders (5) · Urological Manifestations (5) · Pathologic Processes (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)
Adalimumab (2) · 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide (1) · Abatacept (1) · Atorvastatin (1) · CCX140-B (1) · Cyclophosphamide (1) · Dexamethasone (1) · Galactose (1) · Glucose (1) · Irbesartan (1) · Isotretinoin (1) · Lisinopril (1) · Losartan (1) · Plasma Exchange (1) · Plasmapheresis (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) · Amgen (1) · Biogen (1) · Bristol-Myers Squibb (1) · Dimerix Bioscience Pty Ltd (1) · Duke University (1) · GlaxoSmithKline (1) · NYU Langone Health (1) · River 3 Renal Corp. (1) · Travere Therapeutics, Inc. (1) · University Hospital, Limoges (1) · University of Michigan (1) · Vertex Pharmaceuticals Incorporated (1)
United States (15) · France (4) · Canada (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Italy (2) · Czechia (1) · Germany (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Puerto Rico (1)
Jeffrey B Kopp, M.D. (2) · Debbie Gipson, MD (1) · Howard Trachtman, M.D. (1) · Howard Trachtman, MD (1) · Jennifer Gassman, PhD (1) · Opeyemi Olabisi, MD (1) · Simon Roger, MD (1) · Zubin Modi, MD (1)
PMID 35224732, PMID 40337980, PMID 38724717, PMID 19073787, PMID 19932542, PMID 21310077, PMID 26198842, PMID 30361325, PMID 33767059, PMID 35230699, PMID 36657027, PMID 36920755, PMID 38831932, PMID 39513526, PMID 39808779, PMID 41236849, PMID 41774497
2015 (1), R01MD016401 (1), R33DK070341 (1)